Immunome IMNM Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $14.22M+9.1% | $11.72M-8.7% | $11.48M-5.4% | $12.22M+35.8% | $13.03M+144% | ||
| $4.02M-63.3% | $6.94M-23.2% | $9.68M-4.4% | $12.59M+16.7% | $10.94M-13.8% | ||
| $186.8M+23.7% | $177.29M+36.9% | $174.41M+91.0% | $162.41M+180% | $151.05M+337% | ||
| $46.03M+22.3% | $43.77M+32.8% | $42.12M+37.9% | $40.7M+60.3% | $37.64M+65.5% | ||
| $242.82M+6.0% | $231.05M-26.6% | $243.9M-25.6% | $237.2M-16.0% | $229.08M-8.4% | ||
| -$238.81M-9.5% | -$224.11M+26.7% | -$234.22M+26.2% | -$224.61M+17.3% | -$218.14M+8.1% | ||
| -5,947.9%-3,954pp | -3,228.8%+154pp | -2,419.9%+714pp | -1,784.1%+734pp | -1,994.3%-123pp | ||
| -$224.59M-9.5% | -$212.39M+27.5% | -$222.74M+27.1% | -$212.39M+19.1% | -$205.11M+11.6% | ||
| -5,593.8%-3,719pp | -3,060%+180pp | -2,301.3%+713pp | -1,687.1%+748pp | -1,875.2%-45.8pp | ||
| -$2.38+25.2% | -$2.42+53.2% | -$2.95+63.6% | -$3.08+59.9% | -$3.18+57.9% | ||
| -$236.35M-9.4% | -$221.65M+27.1% | -$231.94M+26.7% | -$222.5M+17.8% | -$216.12M+8.7% | ||
| -5,886.7%-3,911pp | -3,193.3%+172pp | -2,396.3%+726pp | -1,767.4%+742pp | -1,975.8%-108pp | ||
| -$238.81M-9.5% | -$224.11M+26.7% | -$234.22M+26.2% | -$224.61M+17.3% | -$218.14M+8.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Immunome's income statement data come from?
- Every line is extracted from Immunome's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.